Close Menu
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
What's Hot

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Facebook X (Twitter) Instagram
subjectional.com
Subscribe
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
subjectional.com
Home » ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) Deadline
Featured Health

ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) Deadline

Paul E.By Paul E.October 28, 2024No Comments3 Mins Read
Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP:

Do you own Elanco Animal Health Incorporated (NYSE: ELAN) stock? Did you purchase stock between November 7, 2023 and June 26, 2024? To Elanco Animal Health Incorporated Have you lost money on your investments? Would you like to discuss your rights?

Bernstein Liebhardt LLP, a nationally acclaimed investor rights law firm, represents the Elanco Animal Health, Inc. (“Elanco” or “Company”) (NYSE:ELAN) investment. Reminds the House of the approaching deadline regarding the securities fraud class action lawsuit initiated against the company.

If you purchased or acquired Elanco securities and/or would like to discuss your legal rights and options, please contact the Elanco Animal Health Incorporated Shareholder Class Action Lawsuit or contact Peter Allocco, Investor Relations Manager at (212) 951-2030 or pallocco Please contact us at @bernlieb.com. .

The lawsuit was filed in the United States District Court for the District of Maryland on behalf of investors who purchased or acquired Elanco securities between November 7, 2023 and June 26, 2024 (the “Class Period”). the Securities Exchange Act of 1934 for the Company and certain of its senior officers;

According to the complaint, the defendants made false statements regarding the U.S. Food and Drug Administration’s approval and commercial launch schedule for two of the company’s products, Zenrelia and Credelio Quattro.

If you wish to serve as lead plaintiff in the class action lawsuit, you must file your papers by December 6, 2024. Lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to be the lead plaintiff to participate in the recovery. If you choose to do nothing, you may remain an absent class member.

All representation is done on a contingency fee basis. Shareholders pay no fees or expenses.

Since 1993, Bernstein Liebhardt LLP has recovered more than $3.5 billion for clients. In addition to representing individual investors, our firm is retained by some of the nation’s largest public and private pension funds to monitor their assets and litigate on their behalf. I am. As a result of hundreds of successful class action lawsuits, our firm has been named to the National Law Journal’s Plaintiffs’ Watch List 13 times and ranked on the Legal 500 for 16 consecutive years.

Lawyer advertisement. © 2024 Bernstein Liebhardt Law Offices. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Previous results do not guarantee or predict similar results with respect to future matters.

contact address:

peter allocco
Investor Relations Manager
Bernstein Liebhardt Law Office
https://www.bernlieb.com
(212) 951-2030
pallocco@bernlieb.com



Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleDaxtra selected as Nucleus Research’s 2024 Accelerator of the Year
Next Article 2024 World Series: Aaron Judge’s postseason history doesn’t suggest a turnaround in favor of the Yankees
Paul E.
  • Website

Related Posts

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

June 18, 2025

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

June 5, 2025

Better Choice Company announces SRX Health closure

April 25, 2025
Leave A Reply Cancel Reply

Latest Posts

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Transport Secretary reveals overhaul of aging pneumatic transport systems

Latest Posts

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Welcome to Subjectional!

At Subjectional, we believe that informed opinions are the foundation of a vibrant society. Our mission is to provide insightful, engaging, and balanced information across a diverse range of topics that matter to you. Whether you’re interested in the latest developments in health, navigating the complexities of politics, staying updated on sports, exploring technological advancements, or advancing your career, we’ve got you covered.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Facebook X (Twitter) Instagram Pinterest
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2025 subjectional. Designed by subjectional.

Type above and press Enter to search. Press Esc to cancel.